Stock Watch: Bridgebio’s Endpoint A Bridge Too Far
Switch From Surrogate To Clinical Endpoint Between Phase II and III Had Big Risks
The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.
